GlassScriptPhysician profile
Joseph W Nystrom
NPI 1629006127
$10,523.99
in general payments reported to CMS, 2019-2025
42 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,469 · 2020: $1,735 · 2021: $2,193 · 2022: $1,848 · 2023: $1,256 · 2024: $908 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.65 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,106.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,077.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $924.85 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $742.14 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $729.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.90 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $482.15 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $414.66 | 2019-2025 | |
| Amarin Pharma, INC. | $353.61 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $341.83 | 2019-2023 | |
| Glaxosmithkline, LLC. | $282.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.14 | 2019-2024 | Xifaxan, Ibschek |
| Sumitomo Pharma America, INC. | $254.64 | 2023-2025 | Gemtesa |
| Abbvie INC. | $247.75 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $197.47 | 2022-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Nystrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.